


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 through 28 (cancelled).

29. (Previously presented): Use of the liposome comprising a compound of formula (II)



where:

R₃ is a saturated or unsaturated, straight or branched acyl chain, with 4-26 carbon atoms;

R₄ is a saturated or unsaturated, straight or branched alkyl chain, with 4-26 carbon atoms; and

X⁻ is the anion of a pharmacologically acceptable acid for the transport of drugs or of substances with cosmetic activity.

30. (Currently amended) Use according to claim 29, in which R_3 is preferably selected from the group consisting of nonanoyl, dodecanoyl, myristoyl, palmitoyl, stearoyl ~~or~~ and oleoyl.

31. (Currently amended) Use according to claim 29, in which R_4 is preferably selected from the group consisting of nonyl, undecyl, tetradecyl, hexadecyl ~~or~~ and oleyl.

32. (previously presented) Use according to claim 30, in which X^- is selected from the group consisting of chloride; bromide; iodide; aspartate; acid aspartate; citrate; acid citrate; tartrate; acid tartrate; phosphate; acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate; acid sulphate; trichloroacetate; trifluoroacetate; methane sulphonate; pamoate and acid pamoate.

33. (Currently amended) Use according to ~~claims 29-32~~ claim 29, in which the compound is selected from the group consisting of:

- palmitoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride undecyl ester;
- stearoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine chloride tetradecyl ester;
- myristoyl L-carnitine chloride tetradecyl ester;
- palmitoyl L-carnitine bromide hexadecyl ester; and
- oleoyl L-carnitine chloride oleyl ester.

34. (Currently amended) Use according to claim 29, in which the drug is selected from the group consisting of anticancer, antiangiogenic, antiviral, antibacterial, antifungal, antiprotozoan agents, compounds active on the cardiovascular system, ~~or~~ and immunogenic peptides.

35. (previously presented) Use according to claim 34, in which said drug is an anticancer or antiangiogenic agent.

36. (Currently amended) Use according to claim 35, in which said anticancer agent is selected from the group consisting of taxol ~~or~~ and a derivative of camptothecin.

37. (Currently amended) Use according to claim 36, in which said derivative of camptothecin is selected from the group consisting of

- 7-benzyloxyiminomethylcamptothecin ~~or~~ and
- 7-butoxyiminomethylcamptothecin.

38. (previously presented) Use according to claim 29, in which the liposome additionally contains helper lipids.

39. (Currently amended) Use according to claim 38, in which said helper lipid is selected from the group consisting of cholesterol, 1-palmitoyl-2-oleoyl phosphatidyl choline ~~or~~ and dioleoyl phosphatidyl choline.

40. (Currently amended) A ~~C~~composition comprising a liposome according to claim 29 for the transport of drugs or of a substance with cosmetic activity.

41. (Currently amended) A ~~C~~composition according to claim 40, in which the drug is selected from the group consisting of anticancer, antiangiogenic, antiviral,

antibacterial, antifungal, antiprotozoan agents, compounds active on the cardiovascular system, ~~or~~ and immunogenic peptides.

42. (currently amended) A ~~C~~composition according to claims 40-41, which can be administered orally, parenterally, intravenously, intramuscularly, subcutaneously, transdermally, or in the form of a nasal or mouth spray.